• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Seelos Therapeutics Shares Are Trading Lower By 10%; Here Are 20 Stocks Moving Premarket

    5/30/23 8:12:26 AM ET
    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Telecommunications
    Get the next $ALLR alert in real time by email

    Gainers

    • QualTek Services Inc. (NASDAQ:QTEK) shares rose 206.7% to $0.2350 in pre-market trading after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
    • Wearable Devices Ltd. (NASDAQ:WLDS) shares rose 33.3% to $1.56 in pre-market trading after dropping 17% on Friday. Wearable Devices recently announced its Mudra Band for Apple Watch is available for preorder.
    • Atento S.A. (NYSE:ATTO) shares surged 26.6% to $1.85 in pre-market trading after gaining 8% on Friday.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) gained 23.8% to $0.26 in pre-market trading after declining over 9% on Friday.
    • Gaotu Techedu Inc. (NYSE:GOTU) shares gained 19.7% to $2.98 in pre-market trading after reporting better-than-expected quarterly sales.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares gained 18.8% to $3.78 in pre-market trading after the company reported the FDA approval of INPEFA for the treatment of heart failure..
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) rose 15.1% to $8.69 in pre-market trading after the company reported the FDA acceptance of the Biologics License Application of lifileucel for the treatment of advanced melanoma.
    • Rigetti Computing, Inc. (NASDAQ:RGTI) rose 14.1% to $1.22 in pre-market trading after jumping 34% on Friday.
    • Recruiter.com Group, Inc. (NASDAQ:RCRT) gained 11.2% to $0.24 in pre-market trading after gaining 8% on Friday. Recruiter.com Group recently reported financial results for its first quarter ended March 31, 2023.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) shares climbed 11% to $0.1050 in pre-market trading after dropping around 11% on Friday. T2 Biosystems recently initiated a process to explore a range of strategic alternatives and a restructuring plan, including a reduction in force.

    Losers

    • Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) fell 15.7% to $1.40 in pre-market after gaining around 4% on Friday.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) shares dropped 15.7% to $0.2698 in pre-market trading after jumping around 60% on Friday.
    • IronNet, Inc. (NYSE:IRNT) shares dropped 15.4% to $0.2220 in pre-market trading after climbing 33% on Friday. IronNet 13G Filing showed 3i, LP increased stake in the company to 9.99%.
    • Presto Automation Inc. (NASDAQ:PRST) fell 15.1% to $3.05 in pre-market trading after jumping 64% on Friday. Presto Automation recently entered into commitments for an $10 million common equity pipe.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) fell 12.1% to $0.2750 in pre-market trading after declining 9% on Friday.
    • Quhuo Limited (NASDAQ:QH) fell 11.5% to $1.70 in pre-market trading after climbing over 14% on Friday. Quhuo's homestay sector exceeded $1.754 million in sales during Labor Day holiday.
    • Kubient, Inc. (NASDAQ:KBNT) fell 11% to $0.6501 in pre-market trading. Kubient and Adomni recently announced a definitive merger agreement.
    • TScan Therapeutics, Inc. (NASDAQ:TCRX) shares fell 11% to $2.84 in pre-market trading after jumping 31% on Friday. TScan Therapeutics raised $140 million via secondary stock offering of 23 million at $2 per share and 47 million pre-funded warrants at $2 per share.
    • Oncorus, Inc. (NASDAQ:ONCR) fell 10.4% to $0.1967 in pre-market trading after jumping 10% on Friday. Oncorus recently posted a narrower-than-expected quarterly loss.
    • Seelos Therapeutics, Inc. (NASDAQ:SEEL) fell 10.3% to $0.83 in pre-market trading. On May 23, Nasdaq provided notice to Seelos Therapeutics that it has not regained compliance with rule 5550(A)(2).

     

    Now Read This: Investor Optimism Improves Following Rally in US Stocks

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $ATTO
    $BJDX
    $GOTU

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Rigetti Computing Inc.
    $RGTI
    2/12/2026Buy → Hold
    TD Cowen
    Rigetti Computing Inc.
    $RGTI
    1/22/2026$35.00Neutral → Buy
    B. Riley Securities
    Rigetti Computing Inc.
    $RGTI
    1/15/2026$40.00Buy
    Rosenblatt
    Rigetti Computing Inc.
    $RGTI
    12/17/2025$35.00Outperform
    Wedbush
    Rigetti Computing Inc.
    $RGTI
    12/16/2025$30.00Hold
    Jefferies
    Rigetti Computing Inc.
    $RGTI
    12/11/2025$50.00Outperform
    Mizuho
    TScan Therapeutics Inc.
    $TCRX
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $219,755 worth of shares (150,000 units at $1.47), increasing direct ownership by 9% to 1,804,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/23/26 7:49:43 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rigetti Computing Intends to Invest $100 Million in UK to Accelerate Quantum Computing Development

    BERKELEY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (NASDAQ:RGTI) ("Rigetti" or the "Company"), a pioneer in full-stack quantum-classical computing, today announced that it intends to invest up to $100 million in the UK to accelerate quantum computing development, which will be the Company's first major investment outside of the US. With this investment, the Company plans to deploy a quantum computer with over 1,000 qubits in the next 3 to 4 years. This follows the UK's recently announced program that will dedicate up to £2 billion of government investment with the aim of establishing the UK as a global leader in quantum computing. Rigetti CEO Dr. Subodh Kulkarni

    3/25/26 4:05:00 PM ET
    $RGTI
    EDP Services
    Technology

    Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

    THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced three presentations of sotagliflozin clinical data during the American College of Cardiology (ACC) Annual Meeting. The congress is being held March 28-30 in New Orleans, Louisiana. Lexicon will present data from the Phase 3 SCORED study of sotagliflozin in people with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. In a prespecified analysis, patients were stratified by baseline body mass index (BMI), and the results demonstrated that sotagliflozin reduced heart failure and major adverse cardiovascular events (MACE) irrespective of BMI. Prese

    3/24/26 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on March 19, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 3,400 shares of Iovance's common stock to one new, non-executive employee. The award was granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2023,

    3/20/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rigetti Computing downgraded by TD Cowen

    TD Cowen downgraded Rigetti Computing from Buy to Hold

    2/12/26 7:23:36 AM ET
    $RGTI
    EDP Services
    Technology

    Rigetti Computing upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Rigetti Computing from Neutral to Buy and set a new price target of $35.00

    1/22/26 8:22:22 AM ET
    $RGTI
    EDP Services
    Technology

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Rigetti Computing Inc.

    SCHEDULE 13G/A - Rigetti Computing, Inc. (0001838359) (Subject)

    3/27/26 11:33:37 AM ET
    $RGTI
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Iovance Biotherapeutics Inc.

    SCHEDULE 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    3/27/26 9:52:12 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Wearable Devices Ltd.

    EFFECT - Wearable Devices Ltd. (0001887673) (Filer)

    3/27/26 12:15:13 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lurie Ilana

    3 - Wearable Devices Ltd. (0001887673) (Issuer)

    3/23/26 4:01:02 PM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    SEC Form 3 filed by new insider Barel Shmuel

    3 - Wearable Devices Ltd. (0001887673) (Issuer)

    3/23/26 7:08:54 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    SEC Form 3 filed by new insider Nir Yaacov

    3 - Wearable Devices Ltd. (0001887673) (Issuer)

    3/23/26 7:07:39 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Financials

    Live finance-specific insights

    View All

    Wearable Devices Reports Full Year 2025 Financial Results, Highlights Revenue Growth, $24.4 Million Raised in 2025 and $18.4 Million Cash Position

    YOKNE'AM ILLIT, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (NASDAQ:WLDS, WLDSW)) ("Wearable Devices" or the "Company"), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced its financial results for the year ended December 31, 2025. The Company reported revenue growth for the year, driven in part by a 28.5% increase in sales of its Mudra Link and Mudra Band products, reflecting growing adoption of its gesture-control technology and continued expansion of its business-to-client ("B2C") segment. Management Commentary "We are pleased to conclude 2025 with steady momentum in our B2C sector, drive

    3/12/26 9:00:00 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gaotu Techedu Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    BEIJING, March 5, 2026 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE:GOTU) ("Gaotu" or the "Company"), a leading technology-driven education company in China focused on enabling lifelong learning through AI-powered solutions, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights[1]Net revenues were RMB1,685.3 million, increased by 21.4% from RMB1,388.6 million in the same period of 2024.Gross billings[2] were RMB2,573.7 million, increased by 19.1% from RMB2,160.2 million in the same period of 2024.Loss from operations was RMB118.0 million, compared with loss from operations of RMB149.3 million in the same per

    3/5/26 1:13:00 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Leadership Updates

    Live Leadership Updates

    View All

    Wearable Devices Strengthens AI Advisory Board with Former Google and Qualcomm Executives to Accelerate ai6 Labs' Vision

    Yokneam Illit, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (NASDAQ:WLDS, WLDSW)) ("Wearable Devices" or the "Company"), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced a significant expansion of its AI expert advisory board. This strategic enhancement strengthens the Company's commitment to advancing neural AI innovation through ai6 Labs. The recently launched ai6 Labs is focused on advancing the Company's revolutionary neural AI technology powered by non-invasive electromyography (EMG) technology and the Mudra platform, supporting a closed-loop ecosystem designed to seamlessly connect hu

    3/16/26 8:45:00 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Wearable Devices Expands into Asia's Tech Powerhouse: Secures Exclusive Distribution Agreement in South Korea

    Mudra Band and Mudra Link neural wristbands enter South Korea - a global hub for wearable innovation and home to leading electronics companies such as Samsung Group and LG Electronics Inc. Yokneam Illit, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (NASDAQ:WLDS, WLDSW)) (the "Company" or "Wearable Devices"), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, recently announced that it has entered into an exclusive distribution agreement (the "Agreement") with Sky Commerce Co., Ltd. ("Sky Commerce"), securing a strategic foothold in South Korea - a global hub for wearable innovation and home to leading consume

    11/7/25 9:00:00 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    $ALLR
    $ATTO
    $BJDX
    $GOTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rigetti Computing Inc.

    SC 13G - Rigetti Computing, Inc. (0001838359) (Subject)

    12/5/24 10:15:39 AM ET
    $RGTI
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care